OncoLink en espanõl
Share
Cancer Resources > Cancer News > Cancer News from Reuters > Reuters Cancer News > 2006 > August
Paclitaxel maintenance not recommended for stable metastatic breast cancer
Last Updated: 2006-08-30 13:34:17 -0400 (Reuters Health)
NEW YORK (Reuters Health) - Women with metastatic breast cancer who achieve disease control after six to eight courses of first-line anthracycline plus paclitaxel combination chemotherapy do not benefit from additional courses of paclitaxel.
In a randomized study, published in the August 20th issue of the Journal of Clinical of Oncology, Italian researchers evaluated the outcome of 255 women with stable metastatic breast cancer after first-line chemotherapy with epirubicin or doxorubicin plus paclitaxel. The patients were randomized to eight courses of maintenance therapy with paclitaxel or no additional treatment (controls).
Dr. Alessandra Gennari, of the National Cancer Research Institute, Genoa, and colleagues evaluated disease status every 3 months until progression. The study was prematurely stopped after a futility analysis of 109 patients on paclitaxel maintenance and 106 controls indicated there were no differences between the two groups.
Eighty-four patients assigned to maintenance paclitaxel experienced disease progression, as did 80 of the controls. The median time to disease progression was 8 months and 9 months in the paclitaxel and control groups, respectively. Fifty-two deaths occurred in the paclitaxel group, compared with 46 in the control group. The median survival time was 28 months in the maintenance paclitaxel group and 29 months in the control group.
Patient compliance with maintenance paclitaxel was good. Hematologic toxicity was mild.
Further analysis showed "there was only an 8.6% chance of observing a 3-month improvement in median progression-free survival in the group receiving maintenance paclitaxel," Dr. Gennari's team reports.
"The results provide strong evidence against the hypothesis that maintenance paclitaxel is associated with a clinically worthwhile effect on progression-free survival," the investigators conclude.
J Clin Oncol 2006;24:3912-3918.
Copyright © 2009 Reuters Limited. All rights reserved.
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.